Short Term Statin Treatment & Endothelial Dysfunction Due to Ischemia &

Status Completed

Clinical Trial Summary

Rationale:

Apart from their cholesterol lowering effects, statins have cholesterol‐independent pleiotropic actions, such as upregulation of 5'‐ectonucleotidase and up‐regulation of NO‐synthase that may increase tolerance against ischemia‐reperfusion injury (IR‐injury). Several animal studies have shown reduction of IR‐injury as a result of statin treatment in both the heart and the kidney. Recently the investigators have shown, using Annexin A5 targeting after voluntary ischemic exercise to assess IR‐injury, a protective effect of a 7 day oral rosuvastatin treatment. A three day treatment with atorvastatin however failed to reduce annexin targeting.

Assessment of the flow mediated dilation of the brachial artery as measure of endothelial (dys)function, is a validated model to research effects of possible protective strategies and perform mechanistic experiments on IR‐injury in humans in vivo.

The investigators hypothesize that pretreatment with statins can increase endothelial tolerance against ischemia and reperfusion injury.

Objective:

To study the protective effect of pretreatment (both 3 day and 7 day) with rosuvastatin and atorvastatin on flow mediated dilation after 15 minutes ischemia and 15 minutes reperfusion.

Study design: placebo‐controlled randomised double‐blind trial

Study population: Healthy volunteers, age 18‐50

Intervention: Treatment with either rosuvastatin 20 mg, atorvastatin 80mg or placebo during either 3 or 7 days

Main study parameters: Difference in flow mediated dilation before and after 15 minutes ischemia.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Treatment with rosuvastatin or atorvastatin is not expected to harm the volunteers. Most reported side effects of rosuvastatin and atorvastatin are gastro‐intestinal complains and myalgia. The volunteers will not benefit directly from participating in this study.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00987974
Study type	Interventional
Source	Radboud University
Contact
Status	Completed
Phase	Phase 4
Start date	September 2009
Completion date	March 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02122198` - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women	N/A
Completed	`NCT04156711` - Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery	N/A
Recruiting	`NCT06133634` - Fisetin to Improve Vascular Function in Older Adults	Phase 1/Phase 2
Completed	`NCT05872139` - Role of Mitochondrial-derived Oxidative Stress to Promote Vascular Endothelial Dysfunction in Non-exercisers With Aging	N/A
Recruiting	`NCT04558450` - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN)	N/A
Terminated	`NCT03325933` - Resistance Training and Cardiometabolic Health	N/A
Not yet recruiting	`NCT05939934` - Impact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal	N/A
Completed	`NCT02652975` - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium	N/A
Recruiting	`NCT02334839` - The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction	N/A
Recruiting	`NCT02020044` - Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)	N/A
Completed	`NCT01775865` - Targeting Inflammation to Treat Cardiovascular Aging	Phase 2
Completed	`NCT01691404` - Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO)	N/A
Terminated	`NCT01412216` - The Effects of Sedentarism on Vascular Function, Inflammation, and Insulin Resistance	Phase 2
Completed	`NCT01319344` - Effect of Eplerenone on Endothelial Function in Metabolic Syndrome	Phase 3
Completed	`NCT00848302` - Endothelial Function in Human Arteries	Early Phase 1
Completed	`NCT00990730` - Atherosclerosis in Rheumatoid Arthritis	N/A
Completed	`NCT00532844` - A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction	Phase 2
Completed	`NCT00376246` - Effect of Ezetimibe on Flow-mediated Brachial Artery Reactivity in Healthy Subjects	Phase 4
Completed	`NCT00775099` - Combustion Derived Air Pollution and Vascular Function	N/A
Active, not recruiting	`NCT03388385` - Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms